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To the Editor Interleukin-6 (IL-6) is a pleiotropic cytokine and is a member of Given the pleiotropic nature of IL-6 and its involvement in many types of inflammation, including Th2 induction in T cells, a possible involvement in asthma has been suggested. This has been supported by increased IL-6 levels in the sputum of severe asthma patients and increased IL-6 and sIL-6R in serum during asthma attacks. 7 In addition, murine models of asthma have indicated a beneficial effect of blocking of IL-6R, which was shown to alter the balance between the Th2 cell response and the T-regulatory responses with a greater number of Treg cells produced that had immunosuppressive activity. 5 Furthermore, analysis of GWAS data has identified IL6R SNP as an asthma susceptibility locus. 8 Hawkins et al. have shown genetic association of polymorphisms in the IL6R gene with severity of asthma, high levels of sIL-6R and poor lung function in the SARP cohort. 9 As asthma is a heterogeneous disease, we were interested to investigate whether IL-6 pathway upregulation is associated with particular clinical characteristics. Here, we have used a hypothesisdriven analysis by investigating sputum transcriptomics, sputum and blood proteomics and clinical data in a large cohort of severe nonsmoker asthma patients from the U-BIOPRED consortium. 10 The non-smoker group is defined as those with less than 5 pack-years of smoking and has not smoked for 1 year prior to recruitment. Sputum IL6R mRNA levels were significantly different between healthy individuals (n = 16) and non-smoking patients with severe asthma (n = 61) (fold change 2.78, FDR < 0.002). However, IL6R levels were still heterogeneous within the groups ( Figure 1A ). We used a hierarchical clustering approach starting from genes that are highly correlated with IL6R in the sputum, as these genes are likely to provide biologically relevant connections to the IL-6 pathway. Indeed, pathway analysis using Thomson Reuters MetaCore TM software suite (version 6.24) has shown that these genes were significantly enriched in expected pathways related to immune response signalling including IL-6 signalling, signalling via the JAK-STAT pathway, and inhibition of neutrophil migration in the COPD pathway (FDR < 0.1). There were also statistically significant enrichments for metabolic pathways, oxidation-reduction process, MHC class II protein complex assembly and cell death. We then used these genes that are highly correlated with IL6R to group patients by performing a hierarchical clustering approach. The clustering analysis led to two distinct groups (named severe asthma with high IL6R and low IL6R), as shown in Figure 1B .
The mean levels of the high-IL6R group were 2.8-fold higher than those of the low-IL6R group and 3.5-fold higher than healthy levels, whereas the mean of the low-IL6R group was similar to that of the healthy individuals (FC 1.2), as shown in Figure 1C . The high-IL6R group had significantly (P < .001) higher neutrophil percentages in the sputum (76%) compared with low-IL6R patients (42%) and healthy individuals (42%) ( Figure 1D and Table 1 ). Stratifying patients using the clinical cut-off of high neutrophilia (sputum neutrophils ≥75%) or low neutrophilia (<75%) has led to statistically significant different proportion in the high-and low-IL6R groups (Table 1) . These patients had worse lung function post-bronchodilator ( Table 1 ). The high-IL6R group also had significantly higher levels of IL-6 protein in the sputum and higher levels of serum hCRP and IL-6 (MSD data) ( Table 1 ). Additional analytes from serum including IL-6R (Table 1) , IL-1a and LPS-binding protein, and other analytes (data not shown) measured as described in methods (provided in the supporting document), did not significantly differ between the high-IL-6R and low-IL-6R groups at a threshold of P < .05 and FC > 1.5.
There was no significant difference in percentages of sputum and blood eosinophils, ACQ, FENO, BMI, sex, smoking history, atopy F I G U R E 1 A, Levels of IL6R mRNA in the sputum of patients with severe asthma and healthy controls. B, Heatmap showing hierarchical clustering of patients with severe asthma (columns) and genes correlated with IL6R (rows). C, Sputum IL6R mRNA levels in healthy controls and high-and low-IL6R patients with severe asthma. D, IL6R levels and neutrophil percentages and medication between the two groups ( Table 1) . No significant differences in IL6 blood levels were identified between the high-IL-6R group with high (≥3%) and low (<3%) sputum eosinophils (P-value .78), which supports the independent role of eosinophils in the high-IL6R subgroup. In line with these observations, Peters et al.
recently reported a subpopulation of asthma patients with high IL6
T A B L E 1 Patient characteristics, lung function, sputum and blood cell counts, and selected variables from IL6 pathway from transcriptomics and proteomics levels between the high-and low-IL6R groups Healthy levels are also reported as information. Mean levels and standard deviation of the groups are reported for all variables except for percentage of eosinophils, which is reported as median.
and CRP levels in blood associated with asthma severity and blood neutrophils but not blood eosinophil percentages. 11 However, sputum neutrophil percentages and sputum IL6 mRNA expression levels were not significantly different between the high-and low-IL6 subgroups in that study. 11 These results of higher systemic levels of IL-6 and CRP being associated with the high-IL6 subgroup are consistent with those in our study; however, in contrast we also observed that these patients have neutrophilic airways, as assessed in sputum samples.
We have identified a group of patients with high IL6R mRNA level and high IL-6 protein sputum levels associated with higher sputum neutrophils regardless of eosinophilic inflammation status. This group has also poor lung function and higher levels of systemic IL-6
and CRP. This subpopulation of patients with severe asthma currently has a high unmet clinical need, and they could potentially benefit from therapy targeting the IL-6 pathway. 
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